ONC
BeiGene Ltd - ADR

2,044
Mkt Cap
$37.79B
Volume
5.00
52W High
$385.22
52W Low
$196.45
PE Ratio
657.25
ONC Fundamentals
Price
$341.64
Prev Close
$334.28
Open
$333.43
50D MA
$331.03
Beta
0.68
Avg. Volume
264,859.32
EPS (Annual)
-$6.13
P/B
9.15
Rev/Employee
$346,559.28
Loading...
Loading...
News
all
press releases
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Short Interest Up 24.1% in December
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th...
Business Wire·9d ago
News Placeholder
BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 664 Shares
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 664 shares of the firm's stock in a transaction dated Wednesday, January 7th. The stock was sold at an...
MarketBeat·13d ago
News Placeholder
Is the Options Market Predicting a Spike in BeOne Medicines Stock?
Investors need to pay close attention to ONC stock based on the movements in the options market lately.
Zacks·15d ago
News Placeholder
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA (zanidatamab), a...
Business Wire·16d ago
News Placeholder
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of "Moderate Buy" by Brokerages
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fourteen analysts that are presently covering the company...
MarketBeat·23d ago
News Placeholder
Voya Investment Management LLC Raises Holdings in BeOne Medicines Ltd. - Sponsored ADR $ONC
Voya Investment Management LLC boosted its stake in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) by 49.2% in the third quarter, according to the company in its most...
MarketBeat·27d ago
News Placeholder
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January...
Business Wire·1mo ago
News Placeholder
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 24,369 Shares
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 24,369 shares of the company's stock in a transaction on Tuesday, December 16th. The stock was sold at an...
MarketBeat·1mo ago
News Placeholder
John Oyler Sells 75,631 Shares of BeOne Medicines (NASDAQ:ONC) Stock
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 75,631 shares of the firm's stock in a transaction that occurred on Monday, December 15th. The stock was sold...
MarketBeat·1mo ago
<
1
2
...
>

Latest ONC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.